Analyst Ratings For NASDAQ:IRWD – Ironwood Pharmaceuticals (NASDAQ:IRWD)
Today, NASDAQ:IRWD – Ironwood Pharmaceuticals (NASDAQ:IRWD) stock received an upgrade by Mizuho from Neutral to Buy with a price target of $24.00.
Some recent analyst ratings include
- 5/2/2018-Mizuho Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 4/19/2018-Berenberg Bank initiated coverage with a Buy rating.
- 1/5/2018-Bank of America was Downgraded by analysts at Bank of America from a “Buy ” rating to a ” Underperform” rating. They now have a $15.00 price target on the stock, up previously from $20.00 .
- 12/4/2017-Morgan Stanley Reiterated Rating of Hold.
- 11/27/2017-Credit Suisse Group initiated coverage with a Buy rating.
- On 3/5/2018 Julie Mchugh, Director, sold 1,500 with an average share price of $14.06 per share and the total transaction amounting to $21,090.00.
- On 2/21/2018 Gina Consylman, CFO, sold 3,594 with an average share price of $14.66 per share and the total transaction amounting to $52,688.04.
- On 2/21/2018 Mark G Currie, Insider, sold 1,634 with an average share price of $14.66 per share and the total transaction amounting to $23,954.44.
- On 1/24/2018 Mark G Currie, Insider, sold 60,000 with an average share price of $15.45 per share and the total transaction amounting to $927,000.00.
- On 12/7/2017 Peter M Hecht, CEO, sold 113,405 with an average share price of $15.12 per share and the total transaction amounting to $1,714,683.60.
- On 12/4/2017 Julie Mchugh, Director, sold 1,500 with an average share price of $16.45 per share and the total transaction amounting to $24,675.00.
- On 11/10/2017 Gina Consylman, CFO, sold 864 with an average share price of $15.20 per share and the total transaction amounting to $13,132.80.
Recent Trading Activity for NASDAQ:IRWD – Ironwood Pharmaceuticals (NASDAQ:IRWD)
Shares of NASDAQ:IRWD – Ironwood Pharmaceuticals closed the previous trading session at 19.18 up +0.49 2.62% with 610692 shares trading hands.